Login to Your Account



Roche Legal Worries Aside, Amgen Posts Solid Earnings

By Randall Osborne


Wednesday, October 25, 2006
As some investors fidget over the outcome of an erythropoietin lawsuit against F. Hoffmann-La Roche Ltd., Amgen Inc. posted estimate-beating third-quarter numbers, with earnings of $1.1 billion, or 94 cents per share, compared to $967 million, or 77 cents per share, during the same period last year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription